Neratinib Not Yet Recruiting Phase 2 Trials for Triple Negative Breast Cancer (TNBC) / Her2-Positive Breast Cancer / Early-Stage Breast Cancer Treatment

IndicationsStatusPurposePhase
Not Yet RecruitingTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT03812393Evaluating the Efficacy of Neratinib on Live Cell HER2 Signaling Transduction Analysis Positive Triple Negative Breast